Current Report Filing (8-k)
March 02 2023 - 6:30AM
Edgar (US Regulatory)
0001513525
false
0001513525
2023-02-28
2023-02-28
0001513525
us-gaap:CommonStockMember
2023-02-28
2023-02-28
0001513525
ADIL:WarrantsMember
2023-02-28
2023-02-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
February 28, 2023
Adial Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-38323 |
|
82-3074668 |
(Commission File Number) |
|
(IRS Employer Identification No.) |
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(Address of principal executive offices and
zip code)
(434) 422-9800
(Registrant’s telephone number including
area code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
Common Stock |
|
ADIL |
|
NASDAQ |
|
|
|
|
|
Warrants |
|
ADILW |
|
NASDAQ |
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01. Notice of Delisting or Failure
to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported,
on August 31, 2022, Adial Pharmaceuticals, Inc. (the “Company”) received written notice
from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding
30 consecutive business days (July 20, 2022 through August 30, 2022), the Company’s common stock did not maintain a minimum closing
bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The
Company was provided 180 calendar days, or until February 27, 2023, to regain compliance.
The Company did not regain
compliance with the Minimum Bid Price Requirement by February 27, 2023; however,
on February 28, 2023, the Company received written notification from Nasdaq granting the Company’s request for a 180-day extension
to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved automatically
and without further action if the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of ten consecutive
business days at any time prior to August 28, 2023, Nasdaq will notify the Company that it has regained compliance with the Minimum
Bid Price Requirement and the matter will be closed.
If the Company does not
regain compliance with the Minimum Bid Price Requirement by August
28, 2023, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company
may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing
Rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel,
that such appeal would be successful.
The Company intends to
actively monitor the bid price of its common stock and is considering available options to regain compliance with the Nasdaq listing requirements,
including such actions as effecting a reverse stock split to maintain its Nasdaq listing.
Nasdaq’s extension
notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the Nasdaq
Capital Market under the symbol “ADIL”.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number |
|
Exhibit Description |
104 |
|
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 2, 2023 |
ADIAL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Cary J. Claiborne |
|
Name: |
Cary J. Claiborne |
|
Title: |
President and Chief Executive Officer |
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Jul 2023 to Jul 2024